Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Tariff Threat: Drugs Could Cost U.S. $750M More
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
To assess the potential impact of proposed tariffs on Canadian pharmaceutical imports on U.S. drug costs and supply chains.
Approach:
Research Analysis: A cross-sectional analysis of pharmaceutical drugs manufactured in Canada and exported to the U.S. using data from the National Institutes of Health's DailyMed package inserts database and IQVIA's MIDAS quarterly sales and volume data.
Key Findings:
Approximately $3 billion in U.S. pharmaceuticals depend on Canadian manufacturing.
Proposed 25% tariffs could add $750 million in costs.
28 drugs with no alternative suppliers outside Canada are at risk of supply disruptions.
411 (1.9%) of 22,082 drug products sold in the U.S. market were manufactured in Canada.
Interpretation:
Limitations:
The analysis does not account for immediate impacts of tariffs, which may take months to manifest.
Concerns about upstream dependencies in the pharmaceutical supply chain complicate the assessment.
Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.
